Alvotech is trading at ISK 754.00, up +10.56%, after FDA approval allowed SIMLANDI drug substance for U.S. supply to be made in a second Reykjavik production suite, effectively doubling available manufacturing capacity. - The FDA approval came on October 5, 2026. - Alvotech said the approval further confirms resolution of inspection-related matters at the site. - Coverage explicitly linked the FDA decision to Alvotech’s share rise, supporting it as a company-specific catalyst.